Published February 6, 2025 | Version v1

Oxazole-Based Ferroptosis Inhibitors with Promising Properties toTreat Central Nervous System Diseases

Description

Ferroptosis plays an important role in the occurrence and development of many diseases, including neurodegenerative diseases. Thus, ferroptosis inhibitors able to cross the blood-brain barrier may have therapeutic potential. The bestferroptosis inhibitors so far are lipophilic radical trapping antioxidants (RTAs) that block lipid peroxidation in membranes. Several generations of ferrostatins have been synthesized, among which UAMC-3203 showed high potency in animal models with improved properties compared to ferrostatin-1. To further improve its pharmacokinetic properties, drug-likeness, and permeability, we modified UAMC-3203 by decreasing the size of the molecule and reducing its polarity by replacing the sulfonamide first by amide groups and subsequently by isosteric oxazoles. Herein, we present the design, synthesis, and biological evaluation of a novel series of oxazole RTAs with high potency, excellent oral bioavailability, and high concentrations in brain tissue.

Files

scarpellini-et-al-2025-oxazole-based-ferroptosis-inhibitors-with-promising-properties-to-treat-central-nervous-system.pdf

Additional details

Funding

European Commission
NeuroFerro - Ferroptosis Inhibitors For Neurodegenerative Disorders 101065370